312 related articles for article (PubMed ID: 10078625)
1. Diabetes mellitus: a predictor for late radiation morbidity.
Herold DM; Hanlon AL; Hanks GE
Int J Radiat Oncol Biol Phys; 1999 Feb; 43(3):475-9. PubMed ID: 10078625
[TBL] [Abstract][Full Text] [Related]
2. Incidence of and factors related to late complications in conformal and conventional radiation treatment of cancer of the prostate.
Schultheiss TE; Hanks GE; Hunt MA; Lee WR
Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):643-9. PubMed ID: 7790250
[TBL] [Abstract][Full Text] [Related]
3. Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus.
Kalakota K; Liauw SL
Urology; 2013 Jun; 81(6):1196-201. PubMed ID: 23540863
[TBL] [Abstract][Full Text] [Related]
4. Late GI and GU complications in the treatment of prostate cancer.
Schultheiss TE; Lee WR; Hunt MA; Hanlon AL; Peter RS; Hanks GE
Int J Radiat Oncol Biol Phys; 1997 Jan; 37(1):3-11. PubMed ID: 9054871
[TBL] [Abstract][Full Text] [Related]
5. Commentary on "Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus." Kalakota K, Liauw SL, Department of Radiation Oncology, Northwestern Memorial Hospital, Chicago, IL.: Urology 2013;81(6):1196-201. doi: 10.1016/j.urology.2013.01.047. [Epub 2013 Mar 26].
Gottschalk A
Urol Oncol; 2014 Apr; 32(3):374. PubMed ID: 24679464
[TBL] [Abstract][Full Text] [Related]
6. Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy.
Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg D; Pollack A
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):397-405. PubMed ID: 15890581
[TBL] [Abstract][Full Text] [Related]
7. Late morbidity profiles in prostate cancer patients treated to 79-84 Gy by a simple four-field coplanar beam arrangement.
Chism DB; Horwitz EM; Hanlon AL; Pinover WH; Mitra RK; Hanks GE
Int J Radiat Oncol Biol Phys; 2003 Jan; 55(1):71-7. PubMed ID: 12504038
[TBL] [Abstract][Full Text] [Related]
8. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881
[TBL] [Abstract][Full Text] [Related]
9. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587
[TBL] [Abstract][Full Text] [Related]
10. Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415.
Thor M; Deasy JO; Paulus R; Robert Lee W; Amin MB; Bruner DW; Low DA; Shah AB; Malone SC; Michalski JM; Dayes IS; Seaward SA; Gore EM; Albert M; Pisansky TM; Faria SL; Chen Y; Koontz BF; Swanson GP; Pugh SL; Sandler HM
Radiother Oncol; 2019 Jun; 135():19-24. PubMed ID: 31015166
[TBL] [Abstract][Full Text] [Related]
11. Impact of neoadjuvant androgen ablation and other factors on late toxicity after external beam prostate radiotherapy.
Liu M; Pickles T; Agranovich A; Berthelet E; Duncan G; Keyes M; Kwan W; McKenzie M; Morris J; Pai H; Tyldesley S; Wu J
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):59-67. PubMed ID: 14697421
[TBL] [Abstract][Full Text] [Related]
12. Late gastrointestinal morbidity after three-dimensional conformal radiation therapy for prostate cancer fades with time in contrast to genitourinary morbidity.
Karlsdóttir A; Muren LP; Wentzel-Larsen T; Dahl O
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1478-86. PubMed ID: 18060703
[TBL] [Abstract][Full Text] [Related]
13. Toxicity following high-dose three-dimensional conformal and intensity-modulated radiation therapy for clinically localized prostate cancer.
Shu HK; Lee TT; Vigneauly E; Xia P; Pickett B; Phillips TL; Roach M
Urology; 2001 Jan; 57(1):102-7. PubMed ID: 11164152
[TBL] [Abstract][Full Text] [Related]
14. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 GY) conformal radiotherapy for prostate cancer, using dose-volume histograms.
Boersma LJ; van den Brink M; Bruce AM; Shouman T; Gras L; te Velde A; Lebesque JV
Int J Radiat Oncol Biol Phys; 1998 Apr; 41(1):83-92. PubMed ID: 9588921
[TBL] [Abstract][Full Text] [Related]
15. Intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of a rectal balloon for prostate immobilization: acute toxicity and dose-volume analysis.
Teh BS; Mai WY; Uhl BM; Augspurger ME; Grant WH; Lu HH; Woo SY; Carpenter LS; Chiu JK; Butler EB
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):705-12. PubMed ID: 11172952
[TBL] [Abstract][Full Text] [Related]
16. Low acute gastrointestinal and genitourinary toxicities in whole pelvic irradiation of prostate cancer.
Liu L; Glicksman AS; Coachman N; Kuten A
Int J Radiat Oncol Biol Phys; 1997 Apr; 38(1):65-71. PubMed ID: 9212006
[TBL] [Abstract][Full Text] [Related]
17. Chronic rectal bleeding after high-dose conformal treatment of prostate cancer warrants modification of existing morbidity scales.
Hanlon AL; Schultheiss TE; Hunt MA; Movsas B; Peter RS; Hanks GE
Int J Radiat Oncol Biol Phys; 1997 Apr; 38(1):59-63. PubMed ID: 9212005
[TBL] [Abstract][Full Text] [Related]
18. Acute and Late Genitourinary Toxicity after 72 Gy of Conventionally Fractionated Conformal Radiotherapy for Localised Prostate Cancer: Impact of Individual and Clinical Parameters.
Stankovic V; Džamic Z; Pekmezovic T; Tepavcevic DK; Dozic M; Saric M; Vuckovic S; Nikitovic M
Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):577-86. PubMed ID: 27184943
[TBL] [Abstract][Full Text] [Related]
19. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.
Zelefsky MJ; Levin EJ; Hunt M; Yamada Y; Shippy AM; Jackson A; Amols HI
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1124-9. PubMed ID: 18313526
[TBL] [Abstract][Full Text] [Related]
20. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
